


**UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION**



**IN RE: ZANTAC (RANITIDINE) PRODUCTS
LIABILITY LITIGATION**

MDL No. 2924

(SEE ATTACHED SCHEDULE)


CONDITIONAL TRANSFER ORDER (CTO -99)

On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* 437 F.Supp.3d 1368 (J.P.M.L. 2020). Since that time, 398 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.



FOR THE PANEL:

John W. Nichols
Clerk of the Panel

**IN RE: ZANTAC (RANITIDINE) PRODUCTS
LIABILITY LITIGATION**

MDL No. 2924

SCHEDULE CTO-99 – TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
CALIFORNIA NORTHERN			
CAN	3	22-04730	Hinds, et al. v. ANI Pharmaceuticals, Inc., et al. Opposed 8/29/22
CAN	4	22-04731	Torres, et al. v. ANI Pharmaceuticals, Inc., et al. Opposed 8/29/22
CAN	3	22-04768	Goetz et al v. U.S. Food and Drug Administration
DELAWARE			
DE	1	22-01093	Ard et al v. GlaxoSmithKline, LLC et al
DE	1	22-01094	Acevedo et al v. GlaxoSmithKline, LLC et al
DE	1	22-01095	Adkins et al. v. GlaxoSmithKline, LLC et al